Free Trial

Icon (ICLR) Stock Forecast & Price Target

Icon logo
$164.17 0.00 (0.00%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$164.13 -0.04 (-0.02%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Icon - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
1
Hold
9
Buy
8

Based on 18 Wall Street analysts who have issued ratings for Icon in the last 12 months, the stock has a consensus rating of "Hold." Out of the 18 analysts, 1 has given a sell rating, 9 have given a hold rating, 7 have given a buy rating, and 1 has given a strong buy rating for ICLR.

Consensus Price Target

$174.73
6.43% Upside
According to the 18 analysts' twelve-month price targets for Icon, the average price target is $174.73. The highest price target for ICLR is $209.00, while the lowest price target for ICLR is $100.00. The average price target represents a forecasted upside of 6.43% from the current price of $164.17.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for ICLR and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Icon and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ICLR Analyst Ratings Over Time

TypeCurrent Forecast
10/12/25 to 10/12/26
1 Month Ago
9/12/25 to 9/12/26
3 Months Ago
7/14/25 to 7/14/26
1 Year Ago
10/12/24 to 10/12/25
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
7 Buy rating(s)
7 Buy rating(s)
9 Buy rating(s)
9 Buy rating(s)
Hold
9 Hold rating(s)
7 Hold rating(s)
6 Hold rating(s)
7 Hold rating(s)
Sell
1 Sell rating(s)
2 Sell rating(s)
3 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$174.73$170.40$173.19$210.64
Forecasted Upside6.43% Upside0.64% Upside3.11% Upside14.80% Upside
Consensus RatingHoldHoldHoldModerate Buy

ICLR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ICLR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Icon Stock vs. The Competition

TypeIconHealthcare CompaniesBroader Market
Consensus Rating Score
2.44
2.32
2.53
Consensus RatingHoldHoldModerate Buy
Predicted Upside6.43% Upside927.85% Upside19.60% Upside
News Sentiment Rating
Positive News

See Recent ICLR News
Positive News
Positive News
Report Date
0 Results
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
10/9/2026
Bank of America Corporation logo
Bank of America
4 of 5 stars
UpgradeUnderperform ➝ Neutral$185.00+12.46%
9/30/2026
UBS Group AG logo
UBS Group
4 of 5 stars
Kevin Caliendo
Kevin Caliendo
3 of 5 stars
Initiated CoverageNeutral$195.00+14.47%
9/18/2026
Citigroup Inc. logo
Citigroup
4 of 5 stars
Brendan Digan
Brendan Digan
Not Rated
Lower TargetNeutral$180.00 ➝ $175.00+3.14%
8/26/2026 Reiterated RatingSell (D)
7/31/2026Set Target$194.00+17.42%
7/31/2026Reiterated RatingBuy$207.00 ➝ $209.00+26.26%
7/30/2026 UpgradeStrong-Buy
7/28/2026 UpgradeStrong Sell ➝ Hold
6/26/2026Boost TargetOutperform$180.00 ➝ $190.00+18.04%
6/25/2026Boost TargetOutperform$160.00 ➝ $187.00+14.75%
6/25/2026Boost TargetBuy$164.00 ➝ $197.00+24.55%
6/25/2026UpgradeSector Perform ➝ Outperform$126.00 ➝ $185.00+16.96%
6/25/2026Boost TargetEqual Weight$160.00 ➝ $175.00+10.64%
6/25/2026Boost TargetNeutral$130.00 ➝ $155.00-5.28%
6/1/2026 Set Target$164.00+22.14%
5/29/2026 Reiterated RatingBuy$165.00+22.01%
5/28/2026 DowngradeNeutral
5/28/2026Set Target$145.00+6.18%
2/17/2026Set TargetBuy ➝ Neutral$100.00+7.53%
7/25/2025Boost TargetOutperform$170.00 ➝ $240.00+28.37%
5/2/2025Lower TargetNeutral$180.00 ➝ $160.00+9.30%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 05:26 AM ET.


Should I Buy Icon Stock? ICLR Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, October 8, 2026. Please send any questions or comments about these Icon pros and cons to contact@marketbeat.com.

Icon
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in ICON Public Limited:

  • ICON Public Limited recently beat earnings expectations, reporting $2.56 in earnings per share for the quarter ended July 30, 2026, which exceeded the consensus estimate of $2.55, demonstrating the company's ability to outperform analyst projections and generate strong profitability with a net margin of 3.99%.
  • The stock is currently trading at $164.50, which is below the average analyst price target of $172.40, suggesting potential upside for investors as the consensus rating remains a "Hold" with several analysts, including TD Cowen and BMO Capital Markets, issuing "Buy" or "Outperform" ratings with higher targets.
  • ICON Public Limited has shown strong revenue growth, with quarterly revenue of $2.06 billion in the most recent quarter, up 2.3% year-over-year, and the company has guided for full-year 2026 revenue between $7.9 billion and $8.2 billion, indicating continued expansion in its clinical research services market.
  • Institutional investors have been increasing their holdings in ICON Public Limited, with firms like Principal Financial Group and Franklin Resources raising their stakes in recent quarters, reflecting confidence in the company's long-term growth prospects and stability in the healthcare sector.
  • The company maintains a strong balance sheet with a low debt-to-equity ratio of 0.23, providing financial flexibility to invest in innovation and expand its global operations without significant leverage risk, which is attractive for risk-averse investors.

Icon
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in ICON Public Limited for these reasons:

  • Insider selling has been significant, with directors and executives selling a total of 22,796 shares valued at $3.89 million over the last 90 days, including large sales by directors Ronan Murphy and Eugene McCague, which may signal a lack of confidence in the stock's near-term performance.
  • ICON Public Limited's earnings per share have declined year-over-year, dropping from $3.26 in the same quarter last year to $2.56 in the most recent quarter, indicating potential challenges in maintaining profitability despite revenue growth.
  • The stock has experienced volatility, with a 52-week range of $66.57 to $203.91, and recent price movements, including a 4.7% drop on September 24, 2026, suggest heightened market uncertainty and potential downside risk for investors.
  • Short interest in ICON Public Limited has increased, with 2.63 million shares shorted as of September 15, 2026, representing 6.13% of the float, which could indicate bearish sentiment among traders and potential pressure on the stock price.
  • The company's current ratio of 0.95 and quick ratio of 0.95 suggest limited liquidity to cover short-term liabilities, which could pose challenges in managing cash flow and operational flexibility, especially in a competitive and capital-intensive industry.

ICLR Forecast - Frequently Asked Questions

According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for Icon is $174.73, with a high forecast of $209.00 and a low forecast of $100.00.

18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Icon in the last twelve months. There is currently 1 sell rating, 9 hold ratings, 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ICLR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ICLR, but not buy additional shares or sell existing shares.

According to analysts, Icon's stock has a predicted upside of 6.43% based on their 12-month stock forecasts.

Over the previous 90 days, Icon's stock had 6 upgrades by analysts.

Icon has been rated by research analysts at Bank of America, Citigroup, Robert W. Baird, Truist Financial, UBS Group, Weiss Ratings, William Blair, and Zacks Research in the past 90 days.

Analysts like Icon more than other "healthcare" companies. The consensus rating score for Icon is 2.44 while the average consensus rating score for "healthcare" companies is 2.32. Learn more on how ICLR compares to other companies.


MarketBeat monitors more than a dozen sources for Icon analyst ratings, with the most recent rating issued on 10/9/2026.
From Our Partners